US FDA generics chief moves to new role
This article was originally published in Scrip
Gary Buehler, who has been the head of the US Food and Drug Administration’s Office of Generic Drugs for nearly a decade, is moving to a new role within the agency. In his new position, Mr Buehler will play a key role in negotiations and activities relating to generic drug user fees.
You may also be interested in...
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.
The UK’s Health Research Authority has agreed in principle to implement a new policy that aims to drive a lasting change in clinical trial transparency. Not everyone is convinced.
The UK scheme allows patients with early access to promising new unlicensed medicines when there is a clear unmet medical need.